The Journal of Practical Medicine >
Association of anti⁃neutrophil cytoplasmic antibodies with the disease activity in patients with systemic lupus erythematosus
Received date: 2023-07-25
Online published: 2024-03-26
Objective To investigate the clinical significance of ANCA in the disease activity of patients with SLE. Methods A total of 1 025 SLE patients were recruited and were divided into inactive and active groups according to SLEDAI score. Demographic characteristics， clinical symptoms， autoantibodies， routine laboratory tests and renal pathology were also recorded and compared between the two groups. Results All patients were divided into inactive group （n = 750） and active group （n = 250）. The occurrence of renal， pulmonary， cutaneous， arthritis manifestations were significantly higher than those of the inactive group （all P < 0.05）. All patients were tested for ANCA， and the most common pattern being perinuclear or p-ANCA， the percentage of p-ANCA seropositive increased greatly with the increased disease activity （P < 0.05）. The autoantibodies were further analyzed between the two groups， 25 patients had reactivity to MPO， but no patient had reactivity to PR3. Also， there were significant differences in anti-dsDNA antibody， anti-nucleosome antibody between the two groups （P < 0.05）. In the active group， patients with p-ANCA seropositive exhibited higher serum beta-2-microglobulin （β2-MG）， titers of anti-dsDNA antibody， SLEDAI scores， lower albumin， C3， and C4 levels （P < 0.05）. Meanwhile， p-ANCA was associated with IL-6， which increased significantly with the increase of SLEDAI score. In addition， patients with p-ANCA seropositive had more occurrence of lupus nephritis， but it had no association with the renal pathology. Conclusion The appearance of p-ANCA in SLE patients indicated more severe disease activity status.
Xiaoyi SONG , Chengjie XU , Hangfeng ZHANG , Jiajia. WANG . Association of anti⁃neutrophil cytoplasmic antibodies with the disease activity in patients with systemic lupus erythematosus[J]. The Journal of Practical Medicine, 2024 , 40(5) : 658 -663 . DOI: 10.3969/j.issn.1006-5725.2024.05.012
| 1 | KITCHING A R， ANDERS H J， BASU N， et al. ANCA-associated vasculitis［J］. Nat Rev Dis Primers， 2020， 6（1）：71. doi:10.1038/s41572-020-0204-y |
| 2 | ROSS C， MAKHZOUM J P， PAGNOUX C. Updates in ANCA-associated vasculitis［J］. Eur J Rheumatol， 2022，9（3）：153-166. doi:10.5152/eujrheum.2022.20248 |
| 3 | DOMINGUEZ-QUINTANA M， ALBA M A， HINOJOSA-AZAOLA A. Classification of ANCA-associated vasculitis： differences basedon ANCA specificity and clinicopathologic phenotype［J］. Rheumatol Int， 2021， 41（10）：1717-1728. doi:10.1007/s00296-021-04966-5 |
| 4 | WANG J， GUO H X， CHENG T， et al. Reduced circulating Tregs and positive pANCA were robustly associated with the occurrence of antiphospholipid syndrome in patients with systemic lupus erythematosus［J］. Lupus， 2023， 32（6）：746-755. doi:10.1177/09612033231171287 |
| 5 | PAN Y， HE L. Perinuclear anti-neutrophil cytoplasmic antibody in systemic lupus erythematosus indicates more severe condition［J］. Clin Biochem， 2021，89：38-43. doi:10.1016/j.clinbiochem.2020.12.004 |
| 6 | 闫吉，曹咏. ANCA与其不典型靶抗原在SLE患者血清检测中的临床意义［J］. 中国实验诊断学，2020，24（8）：1284-1285. doi:10.3969/j.issn.1007-4287.2020.08.017 |
| 7 | SANTOS J E， VICENTE R， MALVAR B， et al.Lupus-like nephritis with positive anti-neutrophil cytoplasmic antibodies and negative antinuclear antibodies［J］. J Bras Nefrol， 2022， 44（1）：121-125. doi:10.1590/2175-8239-jbn-2020-0114 |
| 8 | ARINGER M， COSTENBADER K， DAIKH D， et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus［J］. Ann Rheum Dis， 2019， 78（9）：1151-1159. |
| 9 | WANG S， SHANG J， XIAO J， et al. Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody［J］. Ren Fail， 2020，42（1）：244-254. doi:10.1080/0886022x.2020.1735416 |
| 10 | MOISEEV S， COHEN TERVAERT J W， ARIMURA Y， et al. 2020 international consensus on ANCA testing beyond systemic vasculitis［J］. Autoimmun Rev， 2020， 19（9）：102618. doi:10.1016/j.autrev.2020.102618 |
| 11 | PANG Y， RUAN H， WU D， et al. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis［J］. Allergy Asthma ClinImmunol， 2020， 16：37. doi:10.1186/s13223-020-00433-1 |
| 12 | LOU H， LING G S， CAO X. Autoantibodies in systemic lupus erythematosus： From immunopathology to therapeutic target［J］. J Autoimmun， 2022， 132：102861. doi:10.1016/j.jaut.2022.102861 |
| 13 | WEINER M， SEGELMARK M. The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies （ANCA） ［J］. Autoimmun Rev， 2016， 15（10）： 978-982. doi:10.1016/j.autrev.2016.07.016 |
| 14 | LACETERA R， CALATRONI M， ROGGERO L， et al.Prevalence and clinical significance of ANCA positivity in lupus nephritis： a case series of 116 patients and literature review［J］. J Nephrol， 2023，36（4）：1059-1070. doi:10.1007/s40620-023-01574-3 |
| 15 | GAU C C， TSENG M H， WU C Y， et al. The Impact of Serum Anti-neutrophil Cytoplasmic Antibody on Clinical Characteristics and Outcomes in Pediatric-Onset Systemic Lupus Erythematosus Patients［J］. Front Med （Lausanne）， 2021， 8：647510. doi:10.3389/fmed.2021.647510 |
| 16 | TRIVIOLI G， MARQUEZ A， MARTORANA D， et al. Genetics of ANCA-associated vasculitis： role in pathogenesis， classification and management［J］. Nat Rev Rheumatol， 2022， 18（10）：559-574. doi:10.1038/s41584-022-00819-y |
| 17 | 胡静，黄卓春，王丽，等. ANCA及其特异性抗体在SLE患者中的应用价值初探［J］. 国际检验医学杂志，2021， 42（11）：1281-1290. doi:10.3969/j.issn.1673-4130.2021.11.001 |
| 18 | VOJDANI A， VOJDANI E， HERBERT M， et al. Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA［J］. Int J Mol Sci， 2020，21（4）：1381. doi:10.3390/ijms21041381 |
| 19 | SHEN P， HAN L， CHEN G， et al. Emodin Attenuates Acetaminophen-Induced Hepatotoxicity via the cGAS-STING Pathway［J］. Inflammation， 2022， 45（1）：74-87. doi:10.1007/s10753-021-01529-5 |
| 20 | WEINSTEIN A， ALEXANDER R V， ZACK D J. A Review of Complement Activation in SLE［J］. Curr Rheumatol Rep， 2021， 23（3）：16. doi:10.1007/s11926-021-00984-1 |
| 21 | YOU T， LIN X， ZHANG C， et al. Correlation between serum β2-microglobulin level and systemic lupus erythematosus disease activity：A PRISMA-compliant meta-analysis［J］. Medicine （Baltimore）， 2022， 101（39）：e30594. doi:10.1097/md.0000000000030594 |
| 22 | LIU L， WANG R， DING H， et al. The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients［J］. PLoS One， 2020， 15（10）：e0240942. doi:10.1371/journal.pone.0240942 |
| 23 | SAID D， RASHAD N M， ABDELRAHMANC N S， et al. Antineutrophil cytoplasmic antibody in lupus nephritis： correlation with clinicopathological characteristics and disease activity［J］. Curr Rheumatol Rev， 2021，17（2）：213-221. doi:10.2174/1573397116999201208213422 |
| 24 | 凌磊，皮肖冰，余旸弢，等. 系统性红斑狼疮患者血清干扰素-α的水平变化及其临床意义［J］. 实用医学杂志， 2016， 32（1）：106-108. doi:10.3969/j.issn.1006-5725.2016.01.033 |
| 25 | ARINGER M. Inflammatory markers in systemic lupus erythematosus［J］. J Autoimmun， 2020， 110： 102374. doi:10.1016/j.jaut.2019.102374 |
/
| 〈 |
|
〉 |